We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Advanced Imaging Reveals Hidden Metastases in High-Risk Prostate Cancer Patients

By MedImaging International staff writers
Posted on 06 Jan 2025
Print article
Image: PSMA-PET/CT images of an 85-year-old patient with hormone-sensitive prostate cancer (Photo courtesy of Dr. Adrien Holzgreve)
Image: PSMA-PET/CT images of an 85-year-old patient with hormone-sensitive prostate cancer (Photo courtesy of Dr. Adrien Holzgreve)

Prostate-specific membrane antigen–portron emission tomography (PSMA-PET) imaging has become an essential tool in transforming the way prostate cancer is staged. Using small amounts of radioactive “tracers,” or radiotracers, that bind to prostate cancer cells, PSMA-PET makes these cells visible on PET scans. In contrast to traditional imaging, which primarily provides anatomical details, PSMA-PET offers functional imaging that highlights the cancer’s biological activity, significantly improving disease staging accuracy. While PSMA-PET’s clinical adoption has revolutionized prostate cancer imaging, treatment decisions still often rely on clinical trials that did not incorporate this advanced imaging technique for patient selection. Now, a new study has shown that high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously believed. Published in JAMA Network Open, the study found that nearly half of high-risk prostate cancer patients, initially classified as nonmetastatic by conventional imaging, were later found to have metastatic disease when assessed using PSMA-PET. This suggests that traditional imaging might often underestimate the extent of cancer spread.

To further investigate the advantages of PSMA-PET over conventional imaging, researchers at the UCLA Health Jonsson Comprehensive Cancer Center (Los Angeles, CA, USA) conducted a post hoc, retrospective cross-sectional study using data from 182 patients with high-risk recurrent prostate cancers who were previously thought to have disease limited to the prostate and eligible for the EMBARK trial. This clinical trial had previously demonstrated that adding enzalutamide, a type of hormone therapy, to androgen deprivation therapy improved metastasis-free survival. However, the trial relied on conventional imaging to classify patients, a method the researchers believe might have underestimated the disease’s spread in some instances. In this cohort, the researchers found that PSMA-PET detected cancer metastases in 46% of patients, even though traditional imaging had shown no evidence of spread. Moreover, based on PSMA-PET, 24% of the patients had five or more lesions missed by conventional imaging.

These findings challenge the conclusions of earlier studies, such as the EMBARK trial, and advocate for the inclusion of PSMA-PET in patient selection for future clinical and trial interventions in prostate cancer. They also suggest a need to reassess treatment strategies and open the possibility for potentially curative treatments, like targeted radiotherapy, for some patients. The results raise important questions about how new imaging technologies should be integrated into standard clinical care. While the study highlights the significant potential of PSMA-PET, ongoing research is needed to better understand its impact on long-term patient outcomes and how it can best inform therapy, as noted by the researchers.

“We anticipated that PSMA-PET would detect more suspicious findings compared to conventional imaging. However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases,” said Dr. Adrien Holzgreve, a visiting assistant professor at the David Geffen School of Medicine and first author of the study. “We have good rationales to assume that it is helpful to primarily rely on PSMA-PET findings. But more high-quality prospective data would be needed to claim superiority of PSMA-PET for treatment-guidance in terms of patient outcome. However, we are confident PSMA-PET will continue to advance prostate cancer staging and guide personalized therapies.”

40/80-Slice CT System
uCT 528
New
Digital X-Ray Detector Panel
Acuity G4
Mobile Barrier
Tilted Mobile Leaded Barrier
Multi-Use Ultrasound Table
Clinton

Print article

Channels

Ultrasound

view channel
Image: Artificial intelligence can improve ovarian cancer diagnoses (Photo courtesy of 123RF)

AI-Based Models Outperform Human Experts at Identifying Ovarian Cancer in Ultrasound Images

Ovarian tumors are commonly found, often by chance. In many regions, there is a significant shortage of ultrasound specialists, which has raised concerns about unnecessary medical interventions and delayed... Read more

General/Advanced Imaging

view channel
Image: Automated methods enable the analysis of PET/CT scans (left) to accurately predict tumor location and size (right) (Photo courtesy of Nature Machine Intelligence, 2024. DOI: 10.1038/s42256-024-00912-9)

Deep Learning Based Algorithms Improve Tumor Detection in PET/CT Scans

Imaging techniques are essential for cancer diagnosis, as accurately determining the location, size, and type of tumors is critical for selecting the appropriate treatment. The key imaging methods include... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.